"Oxazolidinones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.
| Descriptor ID |
D023303
|
| MeSH Number(s) |
D03.383.129.462.600
|
| Concept/Terms |
Oxazolidin-2-one- Oxazolidin-2-one
- Oxazolidin 2 one
- 2-oxazolidinone
- 2 oxazolidinone
- 2-Oxazolidone
- 2 Oxazolidone
- 1,3-Oxazolidin-2-one
- 1,3 Oxazolidin 2 one
- 1,3-Oxazolidine-2-one
- 1,3 Oxazolidine 2 one
|
Below are MeSH descriptors whose meaning is more general than "Oxazolidinones".
Below are MeSH descriptors whose meaning is more specific than "Oxazolidinones".
This graph shows the total number of publications written about "Oxazolidinones" by people in this website by year, and whether "Oxazolidinones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 6 | 0 | 6 |
| 2005 | 2 | 0 | 2 |
| 2010 | 3 | 0 | 3 |
| 2011 | 3 | 1 | 4 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 1 | 3 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oxazolidinones" by people in Profiles.
-
Antibacterial Activity of Tedizolid, a Novel Oxazolidinone Against Methicillin-Resistant Staphylococcus aureus: A Systematic Review and Meta-Analysis. Microb Drug Resist. 2019 Nov; 25(9):1330-1337.
-
A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. Am J Cardiol. 2017 Aug 15; 120(4):569-576.
-
Cadazolid for the treatment of Clostridium difficile. Expert Opin Investig Drugs. 2017 Apr; 26(4):509-514.
-
Novel antibiotics in development to treat Clostridium difficile infection. Curr Opin Gastroenterol. 2017 01; 33(1):1-7.
-
Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. Am J Cardiol. 2017 Feb 01; 119(3):388-396.
-
In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients. J Antibiot (Tokyo). 2014 Jul; 67(7):505-9.
-
A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis. 2014 Jul 01; 59(1):51-61.
-
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. Eur Heart J. 2013 Jun; 34(24):1783-9.
-
Spectrum of gram-positive bacteraemia and in vitro activities of daptomycin, linezolid and vancomycin against organisms isolated from cancer patients. Int J Antimicrob Agents. 2013 Jun; 41(6):516-20.
-
Update on therapies targeting HDL: the mystery continues. Curr Opin Lipidol. 2011 Dec; 22(6):514-6.